Proteome SciencesPMSNF Debt-to-EBITDA is -14.83 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 884954.87% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Proteome Sciences's Debt-to-EBITDA or its related term are showing as below:
PMSNF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.85 Med: -5.22 Max: 27.95
Current: -9.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of Proteome Sciences was 27.95. The lowest was -11.85. And the median was -5.22.
PMSNF's Debt-to-EBITDA is ranked worse than 100% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.3
vs PMSNF: -9.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Proteome Sciences Debt-to-EBITDA Related Terms
Proteome Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMSNF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Proteome Sciences (PMSNF) has a Debt-to-EBITDA of -14.83 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Proteome Sciences. According to the industry distribution chart, Proteome Sciences ranks #999999 out of 113 companies in the Medical Diagnostics & Research industry.
Is Proteome Sciences' Debt-to-EBITDA too high?
Proteome Sciences' current Debt-to-EBITDA is -14.83. Based on the distribution chart, Proteome Sciences ranks #999999 out of 113 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #999999 out of 113 companies for Debt-to-EBITDA. This places Proteome Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.30, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Proteome Sciences. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current Debt-to-EBITDA is -14.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current Debt-to-EBITDA of -14.83. The stock's GF Value™ is $0.04, compared to a current price of $0.02 — trading 49.4% below its estimated fair value. The current Debt-to-EBITDA is -14.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current Debt-to-EBITDA is -14.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 